Key Highlights:

  • Shares were marked down roughly 4.8% in a micro-cap with a modest free float and wide spreads.
  • FY2026 Revenue rose about 9% to £2.13 million, with gross Margin jumping to 50% from 22%.
  • Stripping out the one-off Finn Therapeutics IP transfer, the underlying margin was a still-improved 43%.
  • Cash climbed to £1.04 million at year-end, more than double the £0.4 million held a year earlier.
  • A US Patent was granted covering the OptiMAL platform’s core design, with applications advancing in Canada, Japan and Australia.

Fusion Antibodies, the Belfast-based antibody engineering specialist, has spent 2026 stitching together contract wins, patent grants and a proprietary discovery platform it hopes will reshape its economics. Yet the shares slipped again in mid-August, a reminder that on AIM a thin, Illiquid micro-cap can drift lower even when the newsflow reads positively. For investors, the question is whether a 9% revenue rebound and a rebuilt cash pile are enough to underpin a still-fragile turnaround.

What happened to the shares?

Fusion Antibodies (LSE:FAB) was marked down by roughly 4.8% in a single session in mid-August 2026, according to a screener snapshot, extending the choppy, low-volume trading that has characterised the stock for much of the year. Because Fusion is a genuine micro-cap with a modest free float and wide bid-offer spreads, a decline of this magnitude can be triggered by a handful of trades rather than any wave of selling. A move of this size in absolute pence terms is small; on a stock priced in the low tens of pence, a 4.8% slip represents only a fraction of a penny of change and should be read in that context rather than as a dramatic collapse.

The precise figure should be treated cautiously. One-day percentage moves on illiquid AIM names frequently reflect the mid-price recalibrating between infrequent trades, so the exact number quoted by a screener may not correspond to a large Volume of shares actually changing hands. What is clear is the broader pattern: Fusion has struggled to build durable upward momentum despite a run of operational milestones through the first half of 2026.

What is driving the story?

No single confirmed company-specific catalyst for the latest share-price movement was identified from the available public information. The most recent regulatory announcement, on 6 August 2026, concerned the acceptance of a patent in Australia — a supportive rather than a negative development — and there was no fresh trading update, profit warning or fundraising notice around the date of the decline to explain the drop.

In the absence of hard news, the most plausible explanations are structural. Fusion’s shares trade thinly, meaning small orders can swing the quoted price disproportionately. Sentiment towards early-stage, cash-consumptive UK life-sciences companies has been fragile, with investors demanding clear paths to profitability before rewarding platform promises. And after a spring trading statement that confirmed only single-digit revenue growth, some holders may simply be reappraising how quickly the company can convert its pipeline and its OptiMAL platform into scaled, recurring income. None of this constitutes a confirmed catalyst; it is the backdrop against which a low-liquidity stock can drift.

Latest company developments

The operational story has been busier than the share price suggests. In its year-end trading statement on 5 May 2026, Fusion pointed to a stream of commercial wins. It secured follow-on contracts extending a stable cell line development programme for a US biotechnology client, a package worth roughly $460,000 with the bulk recognised in the year to March 2026. It also landed a humanisation project with the US specialty division of a global pharmaceutical company and a multi-target Integrated Therapeutic Antibody Services engagement with a European pharma group — evidence that Fusion is winning work from larger, better-capitalised customers.

Grant funding has been another theme. A collaboration with Queen’s University Belfast targeting therapeutic antibodies against DR5, a cancer-relevant target, could deliver up to £545,000 over its duration, and the company issued a further update on that project in June 2026. Fusion also completed a £250,000 antibody intellectual property transfer to Finn Therapeutics, booking a high-margin one-off while retaining collaborative upside.

The strategic centrepiece remains OptiMAL, Fusion’s proprietary antibody discovery library. During the period the company was granted a US patent covering the platform’s core design and methodology, with further applications advancing across jurisdictions including Canada, Japan and Australia. Continued collaboration with the US National Cancer Institute produced what management described as promising validation results, supporting the argument that OptiMAL could generate high-quality antibodies across multiple therapeutic targets. Fusion has floated a potential pipeline value of around £1 million tied to the platform, though converting that into signed revenue remains the crucial test.

Financial position

The headline numbers describe a Business that is recovering from a difficult stretch but is not yet self-sustaining. For the year to 31 March 2026, revenue rose about 9% to £2.13 million from £1.96 million, and the reported gross margin jumped to 50% from 22%, flattered by the one-off Finn Therapeutics IP transfer; stripping that out, the underlying margin was a still-improved 43%. Cash climbed to £1.04 million at the year-end, more than double the £0.4 million held a year earlier — a meaningful rebuild for a company of this size, though the trading statement did not disclose full-year profitability.

The interim figures published in November 2025 underline how uneven the path has been. First-half revenue for the six months to 30 September 2025 fell to £0.84 million from £1.2 million a year before, reflecting the lumpy, project-based nature of contract services. The operating loss narrowed to £540,000 from £794,000, and the net loss improved to £512,000. Reported EBITDA was a loss of £494,000, but excluding the heavy R&D Investment poured into OptiMAL the adjusted EBITDA loss was a much tighter £144,000. Cash at that mid-year point stood at just £252,000, supplemented by £543,000 owed by debtors — a reminder of how narrow the working-capital margin can be between reporting periods.

The bull case

Bulls argue Fusion is executing a credible turnaround from a low base. Revenue is growing again, margins are structurally higher, and the year-end cash balance gives the company more runway than it has enjoyed in some time. The order book is diversifying towards larger pharmaceutical customers, which tend to place bigger, stickier contracts. Above all, OptiMAL offers optionality: if the platform’s patent protection and NCI-backed validation translate into licensing deals or platform-based revenue, the Economics could shift from low-margin service work towards higher-value, more scalable income. At a micro-cap valuation, even modest commercial traction could re-rate the shares.

The bear case

The bear case is equally straightforward. Fusion remains loss-making, its revenue is small and volatile, and a single large contract slipping between periods can swing the numbers materially — as the sharp first-half revenue drop demonstrated. The gross-margin improvement leaned heavily on a one-off IP transfer that will not repeat. OptiMAL, while promising, has yet to prove it can generate substantial recurring revenue, and the roughly £1 million pipeline figure is a potential rather than a booked number. With a thin free float, wide spreads and continued cash consumption from R&D, the stock is vulnerable to sentiment swings and the ever-present risk that the company eventually needs to raise fresh capital.

What could move the shares next?

The next hard catalyst is likely to be the FY2026 audited final results, expected in the autumn of 2026, which will confirm full-year profitability, cash burn and any updated outlook. Beyond that, watch for OptiMAL commercialisation news — a licensing agreement, a paid platform collaboration or further validation data — which would be the clearest evidence that the strategy is working. New contract wins with large pharma, additional grant awards, patent grants in remaining jurisdictions, and any commentary on FY2027 order intake could all move a stock this sensitive. Conversely, a disappointing contract cadence or any hint of a funding requirement would weigh heavily.

Investor takeaway

Fusion Antibodies (LSE:FAB) presents the classic AIM micro-cap tension: tangible operational progress and a genuinely interesting technology platform set against small scale, continued losses and low liquidity. The 9% revenue rebound, the doubled cash balance and the growing roster of Blue-Chip customers are real positives, but the OptiMAL opportunity is still unproven commercially and the business remains project-dependent and cash-consumptive. The mid-August decline appears to owe more to thin trading than to any confirmed setback. Prospective investors should weigh the platform’s optionality against the execution and funding risks, size any position with the stock’s Volatility in mind, and look to the autumn results for firmer evidence of whether the growth story is gaining or losing support.